Clinical Trials
2 trialsNCT02508467 2024-04-12
A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma
Blueprint Medicines Corporation
Phase 1 Completed
NCT04194801 2023-02-06
A Phase Ib/II Study of Fisogatinib(BLU-554) in Subjects With Hepatocellular Carcinoma
CStone Pharmaceuticals
Phase 1/2 Completed